Zhang Wei, Chen Xiao-Ping, Xiang Shuai, Zhang Wan-Guang
Institute of Hepatic Surgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China.
Zhonghua Gan Zang Bing Za Zhi. 2006 Oct;14(10):748-52.
To confirm whether human hepatic progenitor cells (HPCs) occur in human liver cirrhosis, to investigate the relationship between the degree of HPCs activation and the degree of liver inflammation and to provide evidence that HPCs can differentiate into hepatocytes.
Surgical specimens from 30 human cirrhotic livers and from 3 normal livers were investigated by light microscopy and immunohistochemical staining for CK7 (a marker of biliary differentiation) and SMA (a marker of hepatic stellate cell activation). The degree of portal inflammation was determined on routine stained sections. The number of HPCs and intermediate hepatocytes and the extent of the ductular reaction were assessed.
HPCs and ductular reaction were not observed in the normal livers. In liver cirrhosis cases the HPCs originated from the portal areas. With the increase of portal inflammation, HPCs and ductular reaction extending from the periphery of the liver cirrhosis nodules to the liver parenchyma and the intermediate hepatocyte proliferation were observed. The notable hepatic stellate cell activation occurred around the HPCs and ductular reaction. The number of HPCs and the extent of ductular reaction increased significantly as the portal inflammation increased. There were significant correlations between the number of HPCs with the number of intermediate hepatocytes. In addition, there was a strong correlation between the ALT and AST with the number of HPCs and intermediate hepatocytes.
Human hepatic progenitor cell activation exists in human liver cirrhosis. The inflammation is a trigger for HPCs activation. HPCs migration from the portal area to liver parenchyma and their differentiation into hepatocytes are important pathways for liver regeneration.
证实人肝祖细胞(HPCs)是否存在于人类肝硬化中,研究HPCs激活程度与肝脏炎症程度之间的关系,并提供HPCs可分化为肝细胞的证据。
对30例人类肝硬化肝脏手术标本和3例正常肝脏手术标本进行光学显微镜检查及免疫组织化学染色,检测CK7(胆管分化标志物)和SMA(肝星状细胞激活标志物)。在常规染色切片上确定门脉炎症程度。评估HPCs、中间型肝细胞数量及小胆管反应范围。
正常肝脏未观察到HPCs和小胆管反应。在肝硬化病例中,HPCs起源于门脉区。随着门脉炎症加重,观察到HPCs和小胆管反应从肝硬化结节周边向肝实质扩展,中间型肝细胞增殖。在HPCs和小胆管反应周围出现明显的肝星状细胞激活。随着门脉炎症加重,HPCs数量和小胆管反应范围显著增加。HPCs数量与中间型肝细胞数量之间存在显著相关性。此外,谷丙转氨酶(ALT)和谷草转氨酶(AST)与HPCs及中间型肝细胞数量之间存在强相关性。
人类肝硬化中存在人肝祖细胞激活。炎症是HPCs激活的触发因素。HPCs从门脉区向肝实质迁移及其向肝细胞分化是肝脏再生的重要途径。